Therapeutic Biologic GMP Inspections To Become “More Systems-Based”
Executive Summary
Therapeutic biologics manufacturing compliance inspections will move toward the systems-based approach used by the Center for Drug Evaluation & Research, Office of Regulatory Affairs Regional Operations Director Deborah Ralston said
You may also be interested in...
GMP “Pharmaceutical Inspectorate” Being Considered By FDA
FDA is considering creating a dedicated force of inspectors to focus on pharmaceutical manufacturing in an effort to improve the expertise and uniformity of inspections
FDA Systems-Based Inspection Approach To Be Expanded By Early 2002
FDA's systems-based inspection program could be expanded nationwide at the beginning of 2002, CDER Office of Compliance Division of Manufacturing & Product Quality Director Joseph Famulare told the Regulatory Affairs Professionals Society meeting in Baltimore, Md. Nov. 6
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011